PDCD1 and non-small cell lung carcinoma: The addition of the PD-1 inhibitor, pembrolizumab, to the combination of platinum and pemetrexed has recently become the standard first-line therapy for patients with untreated metastatic non-squamous NSCLC without a driver oncogene3.